Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, has formed a strategic collaboration with Merck, known as MSD outside of the U.S. and Canada, in which Arvinas’ novel PROTAC technology will be used to degrade target proteins, with the goal of creating novel therapeutics. The multi-year collaboration will encompass multiple disease targets across several therapeutic areas. While the specifics of the financial arrangements were not d...